Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corporation - Common Stock (NQ:TWST)

38.41 +1.78 (+4.86%)
Streaming Delayed Price Updated: 3:15 PM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Investor Conferences
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody 
From Absci Corporation
Via GlobeNewswire
Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Baird Global Healthcare Conference 2024
From Twist Bioscience Corporation
Via Business Wire
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
From FN Media Group LLC
Via GlobeNewswire
Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Participation in Department of Commerce Consortium Dedicated to AI Safety
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.